[First Japanese Company Selected] Cranebio Inc. Pitches at BioTools Innovator 2026, World's Largest Bio-Accelerator
Cranebio Inc., for the first time as a Japanese company, has been selected for BioTools Innovator 2026, the world's largest accelerator program in life science tools and diagnostics, and pitched its unique technology at an event in the US.
📋 Article Processing Timeline
- 📰 Published: April 30, 2026 at 23:52
- 🔍 Collected: April 30, 2026 at 15:32
- 🤖 AI Analyzed: April 30, 2026 at 15:37 (5 min after Collected)
Cranebio Inc. (Headquarters: Tokyo, Representative Director: Daisuke Yamamoto, hereinafter "Cranebio"), which develops next-generation nucleic acid testing platforms, has been selected as one of 65 companies invited to pitch events for the 2026 BioTools Innovator (hereinafter, BTI) program, the world's largest accelerator program in life science tools and diagnostics. This selection came from over 540 applicants worldwide, marking the first time a Japanese company has been chosen.
Following this, Daisuke Yamamoto, Representative Director, presented at the "WEST COAST PITCH EVENT" held on April 23, 2026, at Thermo Fisher Scientific in Carlsbad, California, USA. On that day, he delivered a presentation on Cranebio's unique DNA origami-based "Molecular Diagnosis Platform" and "At-home HPV screening," which garnered significant interest from local investors and industry experts.
Amidst investors and experts from various countries around the world, Daisuke Yamamoto, Representative Director of Cranebio Inc., presenting at the pitch, had a valuable opportunity to directly receive local needs and feedback through roundtable discussions.
■ Significance of Selection and Presentation at the Highly Competitive "BioTools Innovator 2026" with Over 8x Selection Rate
BTI is the world's largest non-profit accelerator dedicated to life science research tools and diagnostic technologies. For the 2026 program, there were over 540 applicants worldwide, and only 65 companies were invited to the pitch event after rigorous screening (a selection rate of approximately 8.3x), indicating extremely high competitiveness.
Breaking through this challenge and presenting at the event signifies international high recognition of the innovativeness and market potential of Cranebio's DNA origami technology-based diagnostic platform to solve global healthcare issues. Moving forward, Cranebio will maximize the mentorship from industry experts and the global investor network provided through the program to accelerate business development.
With representatives of innovative startups selected for BioTools Innovator 2026, the world's largest accelerator, and the accelerator team supporting their growth.
■ Presentation Content: Addressing the "Testing Gap" with At-Home HPV Testing to Rectify Healthcare Disparities
At this event, held at global biotechnology company Thermo Fisher Scientific, Representative Yamamoto proposed solutions to the following social issues:
Approach to Unscreened Issues: He highlighted the current situation in developing countries like India and Africa, in addition to the fact that approximately 25% of women aged 25-65 in the US do not undergo regular HPV screening.
Superiority of Unique Technology: He proposed dramatically lowering testing barriers by offering a self-sampling option at home using Cranebio's "highly sensitive, inexpensive, and disposable" nucleic acid HPV test.
Broad Applicability: He emphasized that this DNA origami-based platform is highly useful not only for HPV but also for other infectious disease tests, such as drug-resistant bacteria (AMR).
■ Future Outlook
With this presentation as a stepping stone, Cranebio will further accelerate the global expansion of its unique DNA origami platform testing. By strengthening global partnerships and promoting clinical development, Cranebio aims to contribute to realizing a world where everyone, everywhere, can access advanced diagnostics.
*First Japanese company: This refers to the fact that the current fiscal year (2026) is the first time a company headquartered in Japan has been selected for BioTools Innovator's official accelerator program and its accompanying official pitch event (based on our own research).
■ About Cranebio Inc.
Cranebio Inc. is a startup that develops innovative molecular diagnostic platforms utilizing DNA origami technology. We aim to rectify global healthcare disparities and improve public health by providing highly sensitive and low-cost testing solutions.
Location: Tokyo
Representative: Daisuke Yamamoto, Representative Director
Business Description: Development of nucleic acid testing platforms using DNA origami technology
URL: [https://www.crane-bio.com/]
■ About BioTools Innovator
BioTools Innovator is the world's largest accelerator program specializing in life science research tools and diagnostic technologies. It provides promising startups with business commercialization support and mentorship opportunities, accelerating the social implementation of technology.
URL: [https://biotools.innovator.org/]
Keywords:
Following this, Daisuke Yamamoto, Representative Director, presented at the "WEST COAST PITCH EVENT" held on April 23, 2026, at Thermo Fisher Scientific in Carlsbad, California, USA. On that day, he delivered a presentation on Cranebio's unique DNA origami-based "Molecular Diagnosis Platform" and "At-home HPV screening," which garnered significant interest from local investors and industry experts.
Amidst investors and experts from various countries around the world, Daisuke Yamamoto, Representative Director of Cranebio Inc., presenting at the pitch, had a valuable opportunity to directly receive local needs and feedback through roundtable discussions.
■ Significance of Selection and Presentation at the Highly Competitive "BioTools Innovator 2026" with Over 8x Selection Rate
BTI is the world's largest non-profit accelerator dedicated to life science research tools and diagnostic technologies. For the 2026 program, there were over 540 applicants worldwide, and only 65 companies were invited to the pitch event after rigorous screening (a selection rate of approximately 8.3x), indicating extremely high competitiveness.
Breaking through this challenge and presenting at the event signifies international high recognition of the innovativeness and market potential of Cranebio's DNA origami technology-based diagnostic platform to solve global healthcare issues. Moving forward, Cranebio will maximize the mentorship from industry experts and the global investor network provided through the program to accelerate business development.
With representatives of innovative startups selected for BioTools Innovator 2026, the world's largest accelerator, and the accelerator team supporting their growth.
■ Presentation Content: Addressing the "Testing Gap" with At-Home HPV Testing to Rectify Healthcare Disparities
At this event, held at global biotechnology company Thermo Fisher Scientific, Representative Yamamoto proposed solutions to the following social issues:
Approach to Unscreened Issues: He highlighted the current situation in developing countries like India and Africa, in addition to the fact that approximately 25% of women aged 25-65 in the US do not undergo regular HPV screening.
Superiority of Unique Technology: He proposed dramatically lowering testing barriers by offering a self-sampling option at home using Cranebio's "highly sensitive, inexpensive, and disposable" nucleic acid HPV test.
Broad Applicability: He emphasized that this DNA origami-based platform is highly useful not only for HPV but also for other infectious disease tests, such as drug-resistant bacteria (AMR).
■ Future Outlook
With this presentation as a stepping stone, Cranebio will further accelerate the global expansion of its unique DNA origami platform testing. By strengthening global partnerships and promoting clinical development, Cranebio aims to contribute to realizing a world where everyone, everywhere, can access advanced diagnostics.
*First Japanese company: This refers to the fact that the current fiscal year (2026) is the first time a company headquartered in Japan has been selected for BioTools Innovator's official accelerator program and its accompanying official pitch event (based on our own research).
■ About Cranebio Inc.
Cranebio Inc. is a startup that develops innovative molecular diagnostic platforms utilizing DNA origami technology. We aim to rectify global healthcare disparities and improve public health by providing highly sensitive and low-cost testing solutions.
Location: Tokyo
Representative: Daisuke Yamamoto, Representative Director
Business Description: Development of nucleic acid testing platforms using DNA origami technology
URL: [https://www.crane-bio.com/]
■ About BioTools Innovator
BioTools Innovator is the world's largest accelerator program specializing in life science research tools and diagnostic technologies. It provides promising startups with business commercialization support and mentorship opportunities, accelerating the social implementation of technology.
URL: [https://biotools.innovator.org/]
Keywords: